Lindsay Bealor Greenleaf discusses the administration’s proposed Part B drug model with Fierce Healthcare
Concerns about transparency would extend to Part B if HHS wants to pursue a PBM-esque approach there, Lindsay Bealor Greenleaf, director of ADVI, told Fierce Healthcare.
“It is interesting—the idea of inserting new middlemen into the process, when the administration has raised serious concerns of the role of middlemen on the Part D side of the benefit,” she said.
[el-text]
Written by Paige Minemyer
***excerpt***
Concerns about transparency would extend to Part B if HHS wants to pursue a PBM-esque approach there, Lindsay Bealor Greenleaf, director of ADVI, told Fierce Healthcare.
“It is interesting—the idea of inserting new middlemen into the process, when the administration has raised serious concerns of the role of middlemen on the Part D side of the benefit,” she said.
***end excerpt***
***
[/el-text]
View full article here
Reach out
Own your edge
We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.